natgillin/translations-raw huggingface dataset:
- Pioglitazone Teva Pharma 45 mg tablets are white to off white, round, convex with the number ‘45' on one side and ‘TEVA' on the other side. 
- Pioglitazon Teva Pharma 45 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘45' na jednoj strani i ‘TEVA' na drugoj.
2031GA Haarlem 
Swensweg 5 2031GA Haarlem
6.6 Special precautions for disposal No special requirements for disposal. 
6.4 Posebne mjere pri čuvanju lijeka Lijek ne zahtjeva posebne uvjete čuvanja.
- Pioglitazone Teva Pharma 30 mg tablets are white to off white, round, convex with the number ‘30' on one side and ‘TEVA' on the other side. 
- Pioglitazon Teva Pharma 30 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘30' na jednoj strani i ‘TEVA' na drugoj.
NAME OF THE MARKETING AUTHORISATION HOLDER Teva B.V. 
Nositelj odobrenja za stavljanje gotovog lijeka u promet: Teva B.V.
If you are following a special diet for diabetes, you should continue with this while you are taking Pioglitazone Teva Pharma. 
Ako se pridržavate posebne dijete za šećernu bolest, trebate nastaviti s dijetom dok uzimate
What Pioglitazone Teva Pharma looks like and contents of the pack - Pioglitazone Teva Pharma 15 mg tablets are white to off white, round, convex with the number 
Kako Pioglitazon Teva Pharma izgleda i sadržaj pakiranja - Pioglitazon Teva Pharma 15 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘15' na jednoj strani i ‘TEVA' na drugoj.
Pioglitazone Teva Pharma 15 mg tablets Pioglitazone Teva Pharma 30 mg tablets Pioglitazone Teva Pharma 45 mg tablets 
Pioglitazon Teva Pharma 15 mg tablete Pioglitazon Teva Pharma 30 mg tablete Pioglitazon Teva Pharma 45 mg tablete pioglitazon
- The tablets are supplied in Aluminium/aluminium blisters in packs of 14, 28, 30, 50, 56, 84, 90, 
- Tablete se isporučuju u aluminij/aluminij blisterima u pakiranjima sa 14, 28, 30, 50, 56, 84, 90,
How to take Pioglitazone Teva Pharma 
Kako uzimati Pioglitazon Teva Pharma
Aluminium/aluminium blisters, packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 and 196 tablets. 
Aluminij/aluminij blisteri, pakiranja sa 14, 28, 30, 50, 56, 84, 90, 98, 112 i 196 tableta.
Interactions with substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected. 
Ne očekuju se interakcije s tvarima koje ti enzimi metaboliziraju, npr. oralnim kontraceptivima, ciklosporinom,
Your doctor will ask you to have blood tests periodically during treatment with Pioglitazone Teva Pharma. 
Liječnik će tražiti da za vrijeme liječenja lijekom Pioglitazon Teva Pharma povremeno napravite krvne pretrage, da bi se provjerilo radi li Vaša jetra normalno.
common common uncommon macular oedema not known not known not known not known not known Ear and labyrinth disorders vertigo uncommon 
Poremećaji oka poremećaj vida manje često makularni edem nepoznato nepoznato nepoznato nepoznato nepoznato
How to store Pioglitazone Teva Pharma 
Kako čuvati Pioglitazon Teva Pharma
Pioglitazone Teva Pharma 30 mg tablets 
Pioglitazon Teva Pharma 30 mg tablete
common (may affect up to 1 in 10 people) - respiratory infection - abnormal vision - weight gain - numbness uncommon (may affect up to 1 in 100 people) - inflammation of the sinuses (sinusitis) - difficulty sleeping (insomnia) 
često (mogu se javiti do 1 od 10 osoba) - glavobolja - omaglica - bol u zglobovima - impotencija
Pioglitazone Teva Pharma 45 mg tablets 
Pioglitazon Teva Pharma 45 mg tablete
Each Pioglitazone Teva Pharma 30 mg tablet contains 30 mg of pioglitazone (as hydrochloride). 
Jedna tableta lijeka Pioglitazon Teva Pharma od 30 mg sadrži 30 mg pioglitazona (u obliku pioglitazonklorida).
Pioglitazone Teva Pharma 15 mg tablets 
Pioglitazon Teva Pharma 15 mg tablete
prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4). 
S obzirom na moguće rizike produljene terapije, liječnici koji propisuju lijek trebaju i dalje rutinski procjenjivati nastavak koristi od liječenja pioglitazonom (vidjeti dio 4.4).
Each Pioglitazone Teva Pharma 45 mg tablet contains 45 mg of pioglitazone (as hydrochloride). 
Jedna tableta lijeka Pioglitazon Teva Pharma od 45 mg sadrži 45 mg pioglitazona (u obliku pioglitazonklorida).
Carmellose calcium Hydroxypropylcellulose Magnesium stearate 
FARMACEUTSKI PODACI 6.1 Popis pomoćnih tvari manitol karmelozakalcij hidroksipropilceluloza magnezijev stearat
MARKETING AUTHORISATION NUMBER(S) EU/1/12/758/001-010 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/12/758/001-010
Pioglitazone Teva Pharma should be used every day to work properly. 
Ako prestanete uzimati Pioglitazon Teva Pharma Da bi Pioglitazon Teva Pharma ispravno djelovao, treba ga uzimati svaki dan.
Each Pioglitazone Teva Pharma 15 mg tablet contains 15 mg of pioglitazone (as hydrochloride). 
Jedna tableta lijeka Pioglitazon Teva Pharma od 15 mg sadrži 15 mg pioglitazona (u obliku pioglitazonklorida).
MARKETING AUTHORISATION NUMBER(S) EU/1/12/758/011-020 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/12/758/011-020
Tablet 
14 tableta
31-546, Krakow Poland 
Teva Operations Poland Sp z.o.o. ul. Mogilska 80. 31-546, Krakow
Hepatic impairment 
- abnormalni vid
You can usually continue to take other medicines whilst you are being treated with Pioglitazone Teva Pharma. 
Za vrijeme liječenja lijekom Pioglitazon Teva Pharma obično možete nastaviti uzimati druge lijekove.
The tablets are white to off-white, round, convex and debossed with the number ‘45' on one side and ‘TEVA' on the other side. 
Tablete su bijele do gotovo bijele boje, okrugle, konveksne i imaju oznaku ‘45' s jedne strane i
The tablets are white to off-white, round, convex and debossed with the number ‘15' on one side and ‘TEVA' on the other side. 
Tablete su bijele do gotovo bijele boje, okrugle, konveksne i imaju oznaku ‘15' s jedne strane i
nausea or vomiting). 
Infekcije i infestacije
The tablets are white to off-white, round, convex and debossed with the number ‘30' on one side and ‘TEVA' on the other side. 
Tablete su bijele do gotovo bijele boje, okrugle, konveksne i imaju oznaku ‘30' s jedne strane i
Pioglitazone Teva Pharma 45 mg tablets EU/1/12/758/021-030 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/12/758/021-030
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Pioglitazone Teva Pharma. 
Kad uzimate Pioglitazon Teva Pharma, možete ponovno imati ovulaciju pa mogućnost trudnoće može biti povećana.
This medicine does not require any special storage precautions. 
Nema posebnih zahtjeva za zbrinjavanje.
Mannitol 
Monoterapija
common (may affect up to 1 in 10 people) - headache - dizziness - joint pain - impotence - back pain - shortness of breath - small reduction in red blood cell count - flatulence uncommon (may affect up to 1 in 100 people) - sugar in urine, proteins in urine - increase in enzymes - spinning sensation (vertigo) sweating tiredness increased appetite 
- šećer u mokraći, proteini u mokraći - povišenje enzima - osjećaj vrtnje (vrtoglavica)
Nervous system disorders hypo-aesthesia common common common common common headache common uncommon 
Poremećaji živčanog sustava hipoestezija glavobolja manje često omaglica nesanica manje često manje često manje često manje često manje često
How to store Pioglitazone Teva Pharma Contents of the pack and other information 
Sadržaj pakiranja i druge informacije Što Pioglitazon Teva Pharma sadrži
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 30 mg pioglitazone (as hydrochloride). 
Jedna tableta sadrži 30 mg pioglitazona (u obliku pioglitazonklorida).
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 45 mg pioglitazone (as hydrochloride). 
Jedna tableta sadrži 45 mg pioglitazona (u obliku pioglitazonklorida).
The recommended starting dose is 2.5 mg once a week for 4 weeks. 
Preporučena početna doza je 2,5 mg jednom tjedno tijekom četiri tjedna.
Further information on the orphan designation can be found here: ema.europa.eu/medicines/human/orphan-designations/eu309708. 
Više informacija o statusu lijeka za rijetku bolest nalazi se ovdje: ema.europa.eu/medicines/human/orphan-designations/eu309708.
The medicine can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in treating PKU. 
Lijek se izdaje samo na liječnički recept, a liječenje mora započeti i nadzirati liječnik s iskustvom u liječenju PKU-a.
Palynziq (pegvaliase) 
Palynziq (pegvaliaza)
Further information on Palynziq can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Palynziq. 
Više informacija o lijeku Palynziq nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/Palynziq.
The dose and frequency of injection are then increased gradually (up to a maximum dose of 60 mg once a day) to achieve adequate control of phenylalanine blood levels. 
Doza i učestalost injekcija zatim se postupno povećava (do maksimalne doze od 60 mg jednom dnevno) kako bi se postigla odgovarajuća kontrola razine fenilalanina u krvi.
The most significant allergic reactions include acute systemic allergic reaction, angioedema (swelling under the skin in areas such as the face, throat, arms and legs), and serum sickness (allergic reaction caused by animal proteins or serum). 
Najznačajnije alergijske reakcije uključuju akutnu sistemsku reakciju preosjetljivosti, angioedem (oticanje ispod kože u područjima poput lica, grla, ruku i nogu) te serumsku bolest (alergijsku reakciju uzrokovanu životinjskim proteinima ili serumom).
During the first part, all patients were given Palynziq at a dose of 20 or 40 mg for up to 13 weeks. 
Tijekom prvog dijela svi su bolesnici primili Palynziq u dozi od 20 ili 40 mg u trajanju do 13 tjedana.
Palynziq is available as pre-filled syringes (2.5, 10 and 20 mg) for injection under the skin. 
Palynziq je dostupan kao napunjena štrcaljka (2,5; 10 i 20 mg) za injektiranje pod kožu.
Palynziq is intended for long-term use. 
Palynziq je namijenjen za dugoročnu primjenu.
Palynziq must be used with stringent measures to manage any serious allergic reactions, especially in the first few months. 
Palynziq se mora primjenjivati uz stroge mjere upravljanja bilo kakvim ozbiljnim alergijskim reakcijama, pogotovo u prvim mjesecima terapije.
Palynziq was designated an ‘orphan medicine' (a medicine used in rare diseases) on 28 January 2010. 
Palynziq je dobio status „lijeka za rijetku bolest” 28. siječnja 2010.
The safety of Palynziq is considered acceptable, and important side effects such as allergic reactions are considered manageable with additional stringent measures (see below). 
Sigurnost lijeka Palynziq smatra se prihvatljivom, a značajne nuspojave poput alergijskih reakcija može se kontrolirati uz pomoć dodatnih strogih mjera (vidjeti u nastavku).
In the extension phase of the study patients received an individual optimized dose of Palynziq. 
U fazi nastavka ispitivanja bolesnici su primili individualiziranu optimiziranu dozu lijeka Palynziq.
The enzyme in pegvaliase is ‘pegylated' (attached to a chemical called PEG), allowing it to remain in the body and to act for longer. 
Enzim u pegvaliazi je „pegiliran” (vezan na kemikaliju naziva PEG), što mu omogućava da duže ostane u organizmu i duže djeluje.
The European Medicines Agency therefore decided that Palynziq's benefits are greater than its risks and it can be authorised for use in the EU. 
Europska agencija za lijekove stoga je zaključila da koristi od lijeka Palynziq nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
Why is Palynziq authorised in the EU? 
Zašto je Palynziq odobren u EU-u?
What measures are being taken to ensure the safe and effective use of Palynziq? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Palynziq?
During treatment, monthly measurements are recommended. 
Tijekom terapije preporučuju se mjesečna mjerenja fenilanina.
The most common side effects with Palynziq (which may affect more than 7 in 10 people) are reactions at the injection site, pain in the joints and allergic reactions. 
Najčešće nuspojave lijeka Palynziq (koje se mogu javiti u više od 7 na 10 osoba) su reakcije na mjestu injiciranja, bol u zglobovima i alergijske reakcije.
Palynziq is a medicine that is used to treat phenylketonuria (PKU) in adults and adolescents from 16 years of age. 
Palynziq je lijek za liječenje fenilketonurije (PKU) u odraslih i adolescenata u dobi od 16 godina i starijih.
Side effects reported with Palynziq are carefully evaluated and any necessary action taken to protect patients. 
Nuspojave prijavljene za lijek Palynziq pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
Phenylalanine blood levels must be measured before starting treatment. 
Razine fenilalanina u krvi mora se izmjeriti prije početka terapije.
What is Palynziq and what is it used for? 
Što je Palynziq i za što se primjenjuje?
Palynziq must not be used in patients who have had an allergic reaction to pegvaliase, to any of the other components of Palynziq or to any other pegylated medicine. 
Palynziq se ne smije primjenjivati u bolesnika koji su imali alergijsku reakciju na pegvaliazu, na bilo koji drugi sastojak lijeka Palynziq ili na bilo koji drugi pegilirani lijek.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Palynziq have also been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Palynziq također se nalaze u sažetku opisa svojstava i u uputi o lijeku.
The company that markets Palynziq will provide information material for doctors and for patients and carers about the risk of allergic reactions with Palynziq, including how to identify them promptly and what to do in case such a reaction occurs. 
Tvrtka koja lijek Palynziq stavlja u promet osigurat će informativne materijale za liječnike i bolesnike te njihove njegovatelje o rizicima od alergijskih reakcija pri primjeni lijeka Palynziq, uključujući informacije o tome kako ih odmah prepoznati te kako postupiti u slučaju pojave tih reakcija.
It was shown that for the majority of patients continued treatment with Palynziq for 18 months was effective at keeping blood phenylalanine levels under control (below 600 micromoles per litre). 
Utvrđeno je da je kod većine bolesnika nastavak terapije lijekom Palynziq tijekom 18 mjeseci bio učinkovit u održavanju razina fenilalanina u krvi pod kontrolom (manje od 600 mikromola na litru).
After 8 weeks of treatment, blood phenylalanine levels remained under control in patients taking Palynziq but they returned to pre-treatment levels in patients on placebo, showing that Palynziq was more effective than placebo in reducing blood phenylalanine levels and keeping them within an acceptable range. 
Nakon osam tjedana terapije razine fenilalanina u krvi moglo se kontrolirati u bolesnika koji su primali Palynziq, no vratile su se na razine prije početka terapije u bolesnika koji su primali placebo, što pokazuje da je Palynziq bio učinkovitiji od placeba u smanjivanju razina fenilalanina u krvi i održavanju njegove razine u prihvatljivom rasponu.
As for all medicines, data on the use of Palynziq are continuously monitored. 
Kao i za sve lijekove, podatci o primjeni lijeka Palynziq kontinuirano se prate.
The main study investigating Palynziq in patients with PKU consisted of different parts. 
Glavno ispitivanje lijeka Palynziq u bolesnika s PKU-om sastojalo se od različitih faza.
Eighty-six patients who responded to treatment (i.e. whose blood phenylalanine levels were reduced by at least 20%) where then either kept on the same dose of Palynziq or were given placebo (a dummy treatment). 
Među njima, 86 bolesnika koji su reagirali na terapiju (tj. čije su razine fenilalanina u krvi smanjene za barem 20 %) zadržano je na istoj dozi lijeka Palynziq ili su primili placebo (prividno liječenje).
Other information about Palynziq 
Ostale informacije o lijeku Palynziq
What are the risks associated with Palynziq? 
Koji su rizici povezani s lijekom Palynziq?
For more information about using Palynziq, see the package leaflet or contact your doctor or pharmacist. 
Više informacija o primjeni lijeka Palynziq pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
An overview of Palynziq and why it is authorised in the EU 
Pregled informacija o lijeku Palynziq i zašto je odobren u EU-u
Throughout the study, patients were required to maintain a constant level of dietary protein intake, to ensure that changes in blood phenylalanine levels could be attributed to treatment rather than to changes in protein intake. 
Tijekom ispitivanja bolesnici su morali održavati jednaku razinu unosa proteina hranom kako bi se osiguralo da se promjene razina fenilalanina u krvi može pripisati terapiji, a ne promjenama uzrokovanim unosom proteina hranom.
Palynziq contains the active substance pegvaliase. 
Palynziq sadrži djelatnu tvar pegvaliazu.
The active substance in Palynziq, pegvaliase, is a bacterial enzyme that can break down phenylalanine, thereby stopping phenylalanine from building up in the body and helping to relieve the symptoms of phenylketonuria. 
Djelatna tvar lijeka Palynziq, pegvaliaza, bakterijski je enzim koji razgrađuje fenilalanin, čime onemogućava njegovo nakupljanje u organizmu i pomaže pri ublažavanju simptoma fenilketonurije.
Palynziq was shown to be effective at reducing levels of blood phenylalanine and keeping them under control. 
Lijek Palynziq pokazao se učinkovitim u smanjivanju razina fenilalanina u krvi te u njihovu održavanju pod kontrolom.
Palynziq is used in patients whose blood levels of phenylalanine have not been adequately controlled with other treatments. 
Palynziq se primjenjuje u bolesnika čije se razine fenilalanina na odgovarajući način nisu mogle kontrolirati drugim terapijama.
What benefits of Palynziq have been shown in studies? 
Koje su koristi od lijeka Palynziq utvrđene u ispitivanjima?
How does Palynziq work? 
Kako djeluje Palynziq?
How is Palynziq used? 
Kako se Palynziq primjenjuje?
Patients with this genetic disease cannot process the amino acid phenylalanine from dietary protein, and as a result the amino acid builds up in the blood to abnormally high levels, causing problems in the nervous system. 
Iz tog se razloga aminokiselina nakuplja u krvi do abnormalno visokih razina, uzrokujući probleme u živčanom sustavu.
For the full list of side effects of Palynziq, see the package leaflet. 
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Palynziq potražite u uputi o lijeku.
Anise oil EMA/412178/2016 
EMA/412178/2016
They must also not be used in patients who are allergic to aniseed or to plants of the Apiaceae family (Umbelliferae) (caraway, celery, coriander, dill, fennel) or anethole. 
Također se ne smiju primjenjivati u bolesnika koji su alergični na anišev plod ili biljke iz porodice Apiaceae (Umbelliferae) (kim, celer, korijander, kopar, komorač) ili anetol.
If symptoms last or get worse during the use of the medicine, a doctor or a qualified healthcare practitioner should be consulted. 
Ako se simptomi nastave ili pogoršaju tijekom primjene lijeka, potrebno je obratiti se liječniku ili kvalificiranom zdravstvenom radniku.
Aniseed oil medicines must not be used in children and adolescents under 18 years. 
Lijekovi koji sadrže ulje od aniševa ploda ne smiju se primjenjivati u djece i adolescenata mlađih od 18 godina.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20 September 2016 EMA/412178/2016 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● Ujedinjena Kraljevina
In addition they can be used as an expectorant (a medicine that helps bring up phlegm) for coughs associated with colds. 
Osim toga, mogu se koristiti kao ekspektorans (lijek za olakšavanje iskašljavanja sluzi) za kašalj uslijed prehlade.
Anise oil medicines should only be used in adults and should not be taken for longer than two weeks. 
Lijekovi koji sadrže aniševo eterično ulje smiju se koristiti samo u odraslih osoba osobe i ne smiju se koristiti dulje od dva tjedna.
Anise oil is the common name for the essential oil obtained from the dry ripe fruits of the plant Pimpinella anisum L. 
Aniševo eterično ulje je uobičajeni naziv za eterično ulje koje je dobiveno od suhih zrelih plodova biljke Pimpinella anisum L.
What is anise oil? 
Što je aniševo eterično ulje?
Further information on the HMPC assessment of anise oil medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Daljnje informacije o HMPC-ovoj ocjeni lijekova koji sadrže aniševo eterično ulje, uključujući pojedinosti zaključaka Povjerenstva, mogu se pronaći pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
Further information on the risks associated with these anise oil medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Više o rizicima povezanim s ovim lijekovima koji sadrže aniševo eterično ulje, uključujući odgovarajuće mjere opreza za njihovu sigurnu primjenu, možete pronaći u monografiji pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
Any applications for the licensing of medicines containing anise oil have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC. 
Svi zahtjevi za odobrenje lijekova koji sadrže aniševo eterično ulje moraju se podnijeti nacionalnim tijelima nadležnima za lijekove, koja ocjenjuju zahtjev za biljni lijek i uzimaju u obzir znanstvene zaključke HMPC-a.
Herbal medicines containing these anise oil preparations are usually available in solid or liquid forms to be taken by mouth. 
Biljni lijekovi koji sadrže te pripravke aniševog eteričnog ulja najčešće su dostupni u krutom ili tekućem obliku i uzimaju se kroz usta.
This summary is not intended to provide practical advice on how to use medicines containing anise oil. 
Svrha ovog sažetka nije davati praktične savjete o načinu primjene lijekova koji sadrže aniševo eterično ulje.
Anise oil preparations may also be found in combination with other herbal substances in some herbal medicines. 
Pripravci aniševog eteričnog ulja mogu postojati također i u kombinaciji s drugim biljnim tvarima u nekim biljnim lijekovima.
The HMPC conclusions on the use of these anise oil medicines for indigestion complaints and coughs are based on their ‘traditional use' . 
Zaključci HMPC-a o primjeni ovih lijekova koji sadrže aniševo eterično ulje za probavne tegobe i kašalj temelje se na njihovoj „tradicionalnoj primjeni”.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of anise oil. 
Ovaj dokument predstavlja sažetak znanstvenih zaključaka Povjerenstva za biljne lijekove (HMPC) u pogledu medicinske primjene aniševog eteričnog ulja.
In its assessment, the HMPC considered studies in laboratory tests which showed anise oil to have a relaxing effect on the muscle of the gut and airways. 
Prilikom svoje ocjene HMPC je razmotrio ispitivanja provedena u laboratoriju koja su pokazala da aniševo eterično ulje ima učinak opuštanja mišića crijeva i dišnih putova.
Information on the use and licensing of anise oil medicines in EU Member States should be obtained from the relevant national authorities. 
Informacije o primjeni i davanju odobrenja za lijekove koji sadrže aniševo eterično ulje u državama članicama EU-a mogu se dobiti od nadležnih nacionalnih tijela.
Allergic reactions to aniseed oil that affect the skin or airways may occur. 
Moguće su alergijske reakcije na ulje aniševog ploda koje zahvaćaju kožu ili dišne putove.